Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | TAS2R14 | Q9NYV8 | 14/20 | 0.57 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1287387 | 0.90 | TAS2R14 (0.57) | MEN1KMT2APOLBTAS2R14 | |
| SCHEMBL1287293 | 0.87 | MEN1 (0.60) | MEN1KMT2APOLBTAS2R14CXCR3 | |
| SCHEMBL1287531 | 0.86 | MEN1 (0.50) | MEN1KMT2APOLBTAS2R14CXCR3 | |
| SCHEMBL1287315 | 0.84 | MEN1 (0.70) | MEN1KMT2APOLBTAS2R14CXCR3 | |
| SCHEMBL1287273 | 0.84 | MEN1 (0.89) | MEN1KMT2APOLBTAS2R14CXCR3 | |
| SCHEMBL1287420 | 0.83 | TRPM8 (0.51) | MEN1KMT2APOLBTAS2R14 | |
| SCHEMBL1287473 | 0.82 | MEN1 (0.65) | MEN1KMT2APOLBTAS2R14CXCR3 | |
| SCHEMBL1287415 | 0.80 | TP53 (0.61) | MEN1KMT2APOLBTAS2R14CXCR3 | |
| SCHEMBL1287431 | 0.78 | MEN1 (0.65) | MEN1KMT2APOLBTAS2R14CXCR3 | |
| SCHEMBL1287448 | 0.78 | CXCR3 (0.57) | MEN1KMT2APOLBTAS2R14CXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012047926-A2 | SULFONAMIDE-CONTAINING COMPOUNDS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2012-04-12 | — | — | WO | disclosed |